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Research Article
A multiplexed bead assay for profiling
glycosylation patterns on serum protein
biomarkers of pancreatic cancer
A multiplexed bead-based immunoassay was developed to simultaneously profile
glycosylation patterns of serum proteins to investigate their usefulness as biomarkers for
pancreatic cancer. The multiplex assay utilized protein-specific capture antibodies
chemically coupled individually to beads labeled with specific amounts of fluorescent
dye. Captured proteins were detected based on the extent and specific type of glycosyl-
ation as determined by successive binding of fluorescent lectin probes. Advantages to this
technique include the fact that antibodies coupled to the beads had minimal nonspecific
binding to the lectins ConA/SNA, avoiding the step of chemically blocking the antibody
glycans and the bead assays were performed in a 96-well filter plate enabling high-
throughput screening applications with improved reproducibility. The assay was tested
with ConA and SNA lectins to examine the glycosylation patterns of a-1-b glycoprotein
(A1BG) and serum amyloid p (SAP) component for use as potential biomarkers for the
detection of pancreatic cancer based on the results from prior biomarker studies. The
results showed that the SNA response on the captured A1BG protein could distinguish
chronic pancreatitis samples from pancreatic cancer with a p-value of 0.035 and for the
SAP protein with SNA, a p-value of 0.026 was found between the signal of normal
controls and the pancreatic cancer samples. For the ConA response, a decline in the
signal for both proteins in the serum samples was found to distinguish pancreatic cancer
from normal controls and renal cell carnoma samples (A1BG, po0.05; and SAP,
po0.0001).
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1 Introduction
Carbohydrate modifications on glycoproteins show a high-
structural diversity reflecting inherent functional roles for
particular biological environments [1–7]. Serum represents
one of the most physiologically relevant glycoproteomes in
the human body. The alteration of glycan structure and
coverage on several major glycoproteins in serum has been
shown to be associated with the progression of cancer
[8–12]. Studies comparing the carbohydrate chains of
glycoproteins produced in serum from patients with
developed malignancy to patients with corresponding
chronic disease and normal controls may provide useful
information for the diagnosis, prognosis, and the develop-
ment of therapeutic strategies [13–17].
Pancreatic adenocarcinoma is the fourth leading cause
of cancer-related death in the United States [18]. According
to the SEER (Surveillance, Epidimiology and End Results)
database, pancreatic adenocarcinoma is associated with a
4% 5-year survival rate. While a majority of these patients do
not achieve curability, pancreatic resection is associated with
substantially improved outcomes including a fivefold higher
5-year survival rate [19]. Unfortunately, the overwhelming
majority of patients do not present with early-stage disease
and currently there are no clinically useful strategies for the
detection of early pancreatic cancer. Many strategies utiliz-
ing both invasive and noninvasive techniques have been
employed to detect early pancreatic cancer among patients at
high risk of developing this malignancy. Endoscopic ultra-
sound has been studied for screening purposes but has been
found limited in several aspects [20]. CA 19-9 is a serologic
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detecting early pancreatic cancer [21, 22]. Driven by the
advances in proteomics techniques, a number of efforts have
been made to find new biomarkers in the serum proteome
[23–27]. More recently, a novel mass spectrometry-based
approach has exploited the field of glycomics to discover
unique differential glycosylation patterns of specific proteins
associated with malignant processes [28]. Glycoproteins
from patient serum were extracted and separated by a
combination of multilectin affinity and reverse-phase chro-
matography, then spotted on glass slides. Five lectins were
utilized to investigate the differential glycosylation pattern of
the proteins in each fraction. The study identified potential
glycoprotein biomarkers with a lectin response that could
significantly distinguish between the disease state and the
normal controls.
Microarray immunoassays have been increasingly used
for profiling and characterizing captured proteins and their
modifications, with the appeal of multiplexing and low
sample cost. A new type of antibody-lectin array has been
recently developed to detect the glycosylation of specific
proteins in a complex mixture [29–31]. A variety of glycan
structures of interest can be probed with commercially
available lectins. In glycoprotein research, this technique
provides the highest throughput and reproducibility in
measuring the abundance and glycosylation of multiple
proteins, which is essential for developing an assay for
validation purposes. This sandwich-based assay allows one
to assay a large number of samples based on lectin response
to specific glycan structures while eliminating the need for
any detailed knowledge of the structure which would require
mass spectrometry analysis.
Alternatively, microsphere or bead-based immunoassay
techniques [32, 33] can be used which have similar advan-
tages for this study. Bead-based multiplex protein profiling is
derived from antibody microarrays, but uses polystyrene
beads labeled with amounts of discrete fluorophore instead of
a flat surface for antibody immobilization. The fluorophore
intensity varies between different bead types and is easily
distinguished using a flow cytometer. Additional multi-
plexing capability is achieved through the use of differently
sized beads also distinguishable by flow cytometers.
The advent of the MultiBeadss immunoassay platform
provides beads internally labeled with discrete amounts of
fluorescent dye producing 12 spectrally distinct bead types.
Two sizes of beads are available allowing 24 different bead
types to be combined. Similar to an antibody sandwich assay,
each antibody-coupled bead captures an antigen that can be
detected by a fluorophore-conjugated secondary antibody. A
mixture of bead types, each hosting a separate immunoassay
can be simultaneously read in a flow cytometer. Each reading
contains the measurement of multiple antigens, each differ-
entiated based on the intrinsic fluorescence and size of the
host bead. The beads used in a large set of parallel assays are
uniformly fabricated while for the alternative microarray-
based assays, for example, each block of the microarray is
printed individually providing the potential for bead-based
immunoassays to outperform microarray-based assays in
terms of reproducibility and accuracy. In addition, protein
microarrays typically use noncovalent interactions and
require drying during the printing process to bind the anti-
body to the solid phase. Bead-based immunoassays utilize
covalent linkage chemistry and the immobilized antibodies
are maintained in aqueous buffers. The result is that bead-
based assays typically produce improved background due to
reduced nonspecific absorption.
To take advantage of the benefit of bead-based immu-
noassays for glycosylation detection, we converted an antibody-
lectin technique developed on the microarray platform for use
on the bead platform (experimental scheme shown in Fig. 1).
Two types of antibody-coupled beads targeting a-1-b glyco-
protein (A1BG) and serum amyloid p component as potential
markers from the previous study were prepared and tested to
find the optimal conditions [30]. As a proof-of-concept, the
potential markers are employed to measure the glycosylation
response to SNA (sialylation) and ConA (mannosylation or
complex biantennary glycans) for serum samples from
different groups of patients including pancreatic cancer,
chronic pancreatitis, and normal controls to demonstrate that
we can indeed use this bead-based assay to rapidly distinguish
cancer from normal using this methodology.
2 Materials and methods
2.1 Chemicals
AB34 buffer was obtained from Assay Designs or Enzo Life
Sciences. NaIO4, Tween-20, PBS powder pouch, Brij-35, and
Gly-Cys were purchased from Sigma. 4-(4-N-maleimidophe-
nyl)butyric acid hydrazide hydrochloride (MPBH) was
purchased from Thermo Scientific. All biotinylated
lectins were purchased from Vector Laboratory. Alexa 555-
conjugated streptavidin was purchased from Invitrogen
Biotechnology.
2.2 Serum samples
Sera from 20 patients (10 males) with pancreatic cancer
were obtained at the time of cancer diagnosis in the
Multidisciplinary Pancreatic Tumor Clinic at the University
of Michigan Comprehensive Cancer Center. This was
performed following the completion of informed consent
using IRB-approved guidelines. All patients in the study had
histologically confirmed diagnosis of pancreatic adenocarci-
noma, stage III or IV. None of the patients were actively
undergoing chemotherapy or radiation therapy for pancrea-
tic cancer, or had other malignancies diagnosed or treated
within the previous 5 years. Sera were also obtained from 20
patients (12 males) with chronic pancreatitis in the absence
of acute flare symptoms who were seen in the Gastroenter-
ology Clinic at University of Michigan Medical Center, and
from healthy individuals collected under the auspices of the
Early Detection Research Network (EDRN). The mean age of
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the pancreatic cancer group was 65.2 years (range, 44–83
years) and from the chronic pancreatitis group was 62.6
years (range, 48–83 years).
Inclusion criteria for the study included patients with
pancreatic cancer, chronic pancreatitis, or healthy adults
with the ability to provide written, informed consent. The
samples were permitted to sit at room temperature for a
minimum of 30 min (and a maximum of 60 min) to allow
the clot to form in the red top tubes (Fisher Scientific, 10 mL
glass tubes), and then centrifuged at 1300 g at 41C for
20 min. The serum was removed, transferred to poly-
propylene tubes in 1 mL aliquots, and frozen. The frozen
samples were stored at 801C until assayed. All serum
samples were labeled with a unique identifier to protect the
confidentiality of the patient. None of the samples were
thawed more than twice before analysis.
2.3 Mouse mAbs
A1BG mAb was acquired from Novus, whereas amyloid p
component mAb antibody was from Abcam. The primary
amine groups of the lysines on the mAbs were covalently
coupled to 5.4 mm latex beads via disulfide bridges (Assay
Designs, Enzo Life Sciences, Ann Arbor, MI).
2.4 Antibody blocking
To prevent the reaction between the glycans on the
antibodies and some specific detection lectins, the anti-
bodies coupled to beads were chemically modified following
the glycan-blocking protocol described in our previous study
[30]. Briefly, the beads were washed with coupling buffer
(AB34) and then incubated in 0.2 M NaIO4 for 3 h. When
the oxidation reaction was finished, as determined by where
longer incubation times would not further reduce the
binding of the lectin to the antibody glycans (data not
shown), the precipitate was removed by washing the beads
three times with coupling buffer with 0.1% Tween-20. The
oxidized antibody beads were incubated with 1 mM 4-(4-
N-maleimidophenyl)butyric acid hydrazide hydrochloride
and 1 mM Cys-Gly dipeptide for 2 h. Finally, the beads were
kept in 1 mM Cys-Gly in dark at 41C overnight. The blocked
beads were extensively washed to eliminate reagent in the
solution before being stored in a refrigerator at 41C.
2.5 Sample incubation and flow cytometry detection
The beads coupled to A1BG and serum amyloid p (SAP)
antibodies were mixed with 20 diluted serum (diluted
with PBS containing 0.1% Tween-20 and 0.1% Brij 35) in
Eppendorf tubes and incubated on a shaker set at 300 rpm
for 1 h at room temperature. Each tube contained 6000
beads of each type. The beads were then transferred to two
identical 96-well filter plates where subsequent incubation
and washing were performed. The samples from different
disease groups were randomized on the well plate to
eliminate bias. The two duplicate plates were processed in
parallel. Then, the serum solution was removed and the
beads were washed with PBST three times. A vacuum
Figure 1. The diagram of
bead-based antibody-
lectin multiplex assay. (1)
production of two sizes of
unique labeled beads; (2)
chemical coupling of
different antibodies to
different types of beads;
(3) hybridization of the
antibody-conjugated
beads with diluted serum
in a 96-well filter plate; (4)
sequential reaction of anti-
gen capture, glycan-lectin
binding, and fluorescence
detection; (5) the detection
of signal for each type of
bead with a flow
cytometer; (6) gating
signal points to extract
data for each analyte.
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manifold was used to remove reagent and washing buffer.
Biotinylated lectins (Vector Laboratory) were diluted to
1 ug/mL and applied to each well. The lectin-glycoprotein
reaction was allowed to proceed for 45 min before being
complete. The filter plates were rinsed to remove unbound
lectins. The solution of 1 ug/mL Alexa 555-conjugated
streptavidin (Invitrogen Biotechnology) was added to each
well for detection. Finally, the beads were washed with water
to remove detergent.
The fluorescent signal was read by a flow cytometer
(FACSCalibur). The beads were sorted by the flow cytometer
based on size and inherent fluorescent intensities using the
670 nm filter. Three hundred beads of each type were
counted. The fluorescent signals of the analytes were
measured at 575 nm.
2.6 Statistical analysis
Data analysis was carried out in Weasel version 2.6. Weasel
is a flow cytometry data analysis program available for
download from the Walter and Eliza Hall Institute of
Medical Research. The signals were gated to exclude
damaged or cross-linked beads. The medians of the select
signal spots at each inherent fluorescent level were taken as
a data point into analysis. All the samples were measured
twice with duplicate wells. The reproducibility of the
experiments was assessed by calculating the coefficient of
variation (CV) and Pearson correlation for the pairs of
duplicates. To compare the signal of cancer and noncancer
samples, a Student’ T-test was applied to the data, where a
difference is considered statistically significant when
po0.05.
3 Results and discussion
3.1 Selection of lectins for antibody bead assay
In the antibody array/lectin sandwich assay, the binding of
the lectins to glycans on the antibodies results in
interference for the detection of captured glycoproteins. A
previous study using antibody microarrays for glycoprotein
studies utilized a blocking procedure to prevent this
interaction [30, 31]. As described in Section 2, the cis-diol
groups on the glycans were gently oxidized and converted to
aldehyde groups which then reacted with hydrazide-
maleimide bifunctional cross-linking reagent capped with
a Cys-Gly dipeptide. The fluorescent signal of the lectin
bound to the blocked antibodies decreased five to tenfold
depending on which lectin was used (data not shown). The
derivatization procedure prevented the binding of the lectins
to glycans on the antibodies but it resulted in reduced
stability of the antibody on the antibody-coupled beads,
where the signal of the blocked beads degraded over several
days. To determine whether the glycan-blocking was
necessary, the underivatized beads were treated with/with-
out 20 diluted serum to assess their binding to five
different lectins. The lectins utilized were ConA, SNA, AAL,
MAL II, and PNA as in our previous study on glycoprotein
markers in pancreatic cancer [28].
In Table 1A, the signal of the lectin-treated beads
(without serum) indicates the level of interaction between
an element of the structure and the underivatized bead-
coupled antibodies. This is a distinct advantage in that
derivatizaton of the antibodies to prevent interaction
is not required as most other platforms for ConA and SNA.
The signal of ConA and SNA bound to underivatized
antibodies is 20-fold lower than the signal of the antibody
spots exposed to serum, showing a blocking effect
of the interaction between these two lectins and the
glycans on the antibodies. This response is optimal for our
sandwich assay experiments, especially where SNA is
one of the key lectins used in a prior study for recognizing
changes in a 2–6 sialylation of the glycan structure in
response to a change in disease state. AAL had strong
interaction with the underivatized form which means
that to use AAL for these experiments derivatization would
be required as on the microarray platform. MAL II shows a
low level of background signal in response of the lectin to
the antibodies and could be used in these experiments,
whereas PNA barely binds to the antibodies or the captured
proteins.
From our experience, ConA/SNA frequently binds to
IgG antibodies raised in animals such as mice, sheep, and
rabbits; however, no such binding was observed between the
lectin and the IgGs-conjugated to beads. The same anti-
bodies as those conjugated to the beads were printed on a
microarray and probed with lectin ConA/SNA. Strong
interactions between the lectins and the unblocked anti-
bodies spots were observed, indicating these two antibodies
are normally glycosylated and their glycans are accessible for
the lectins (Table 1B). Only after chemical blocking of the
glycans on the antibodies, as summarized in Table 1C, the
response of the antibodies to the lectins decreased to a level
’10% of the regular signal (for ConA, around 10%). The
process of coupling the antibodies on the beads also
generated an effect of reduced lectin binding on the anti-
bodies similar to the chemical blocking of the glycans.
Although the mechanism for this is not understood at this
time, taking advantage of this property of the bead-conju-
gated antibodies allows us to eliminate several time-
consuming experimental steps in derivatizing the anti-
bodies. Since the underivatized antibodies on the beads do
not bind to ConA and SNA and these two lectins were
important in identifying markers of pancreatic cancer in our
previous study, these two lectins were selected for a trial set
to demonstrate the utility of this method.
3.2 Serum concentration
In these experiments, serum dilution for studying glycosyla-
tion was targeted to antibody saturation and minimization
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of background binding. At antibody saturation, glycosylation
can be studied independently of target glycoprotein serum
concentration since the amount of on-bead glycoprotein is
standardized to the amount of antibody conjugated to the
bead. Thus, differences in glycosylation can be measured
between samples as lectin binding is directly related to the
level of its target glycan structures present on the proteins
captured on the antibody array. In this study, the two
proteins selected were A1BG and SAP which were chosen as
our two best potential markers in response to SNA lectin
based on a previous study [30].
Different dilutions of serum (5, 10, 20, 50, and 200 )
were tested to determine the optimum concentration of the
target glycoproteins. Lectin ConA was used for the detection
in this test. Figure 2 shows the intensity of the signal
changes for the two antibodies with the dilution fold. A
rising trend was noted from the 200 dilution to the 20
dilution for both antibodies. From 20 dilution to 5
dilution, the signal of SAP increased only by 5%. For A1BG,
the signal reached a peak at 20 dilution, where a satura-
tion of the target protein on the antibody had occurred. The
signal then decreased 10% when the dilution increased to
5 . The decrease of signal was observed along with an
increase of outlier data points in the flow cytometry spec-
trum and a higher standard deviation, likely due to
competing nonspecific binding on the antibodies.
The result of the dilution test demonstrated that the
antibodies were saturated by their target protein at 20
dilution in the process of hybridization (1 h, room tempera-
Table 1. Fluorescence signal of antibody-lectin experiment using either antibody-conjugated beads or microarray platform.
Control (incubated with buffer) Incubated with serum
A1BG SAP A1BG SAP
(A) Antibody-conjugated beads without glycan blocking (unit 5 flow cytometer fluorescent unit)
Bead unblocked
SNA 470 32722 537741 68772
MAL 1471 57721 5673 154720
AAL 27675 35379 29177 379711
ConA 470 2276 162718 253733
PNA 270 670 370 871
(B) Antibody microarray without glycan blocking (unit 5 microarray scanner fluorescent unit)
Microarray unblocked
SNA 2193716 60317153 9460778 61627113
MAL 42807252 1429782 39387109 3222760
AAL 22 3127476 24 3677306 19 9587784 22 5627424
ConA 22 1587709 17 18172071 22 0937556 16 6747135
PNA 813737 859716 13587110 15897113
(C) Antibody microarray with glycan blocking (unit 5 microarray scanner fluorescent unit)
Microarray blocked
SNA 338733 176715 79767405 42297226
MAL 28875 226718 27177180 153278
AAL 406714 20279 10 8957444 8446762
ConA 7217128 611748 76637197 60517238
PNA 7171 4372 83713 12272
(A) antibody-conjugated beads were incubated with dilution buffer (left) or diluted serum (right), glycans on the antibodies were not
chemically blocked after conjugation, fluorescent signal of the two antibodies were measured by flow cytometer; (B) antibody
microarrays were incubated with dilution buffer (left) or diluted serum (right), glycans on the antibodies were not blocked after being
printed on microarray; (C) same as (B), but with blocking of antibody glycans.
Figure 2. Signal-dilution curve made to obtain the optimum
concentration of serum for bead hybridization using lectin ConA.
The x-axis is the dilution fold of serum incubated with the beads
in each assay ranging from 5 to 200 , the y-axis is the resulting
fluorescent signal. The value of each spot on the y-axis presents
the signal yield of each assay. A1BG, a-1-b glycoprotein; SAP,
serum amyloid p component. Unit of the fluorescent signal is the
inherent fluorescent unit of the flow cytometer.
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ture, and gentle shaking). Below 20 dilution would not
occupy a majority of all the antibody-binding sites and above
20 dilution could introduce strong nonspecific binding.
Thus, 20 was chosen as the optimal dilution fold.
3.3 Serum testing
Lectin ConA and SNA were used in two separate tests with
antibody-coupled beads to analyze serum samples from
normal control and patients with chronic pancreatitis and
pancreatic cancer. In the experiment using ConA as the
detection lectin, duplicate pairs of 47 samples including ten
normals, ten chronic pancreatitis samples, ten pancreatic
cancer samples, ten renal carcinoma samples, and seven
esophageal cancer samples were incubated with beads on a
single 96-well plate. SNA was used in an experiment to test
20 samples from each of the normal control, chronic
pancreatitis and pancreatic cancer groups and duplicate
wells were made on two identical plates.
3.3.1 Reproducibility
The reproducibility of the samples incubated on the same
plate or two different plates were assessed using the results
of ConA and SNA experiments, respectively. For the ConA
experiment performed on a single plate, the average CVs of
the duplicate pairs for antibody A1BG and SAP were 9.8 and
6.9%, respectively. In the SNA experiment, the average CVs
of the duplicate pairs on two different plates for antibody
A1BG and SAP were 7.5 and 5.9%, respectively. The intra-
assay variability can be decreased by gating out signals of
some damaged beads generated from cross-linked beads or
nonspecific binding.
3.3.2 Biomarker performance
The proteins A1BG and SAP were found to be pancreatic
cancer-related biomarker candidates based on their response
to SNA lectin [28, 30]. Their glycosylation levels were found
to be elevated in pancreatic cancer serum in this study using
a RP HPLC-fraction microarray method [28]. Both of these
two glycoproteins produced significant differences when
analyzed against lectin SNA and ConA. Their potential to
aid diagnosis in pancreatic cancer was further tested
utilizing the antibody microarray with lectin SNA in a
previous study against 183 samples from various groups
[30]. The results determined that A1BG was able to
distinguish pancreatic cancer from chronic pancreatitis.
On the bead-based platform, a similar experiment was
Figure 3. Result of an experiment using ten sera samples from
patients with stages III and IV pancreatic adenocarcinoma,
chronic pancreatitis, and normal healthy controls. Glycans of
the two captured proteins, (A) serum amyloid p component;
(B) A1BG were probed with biotinylated SNA and detected by
streptavidinylated Alexa555. The bar graph and SEM (error bars)
shows the average signal and variation for each group of
samples. The group marked with a green star on top can be
significantly distinguished from the group marked with a red
star. Unit of the fluorescent signal is the inherent fluorescent unit
of the flow cytometer.
Figure 4. Result of an experiment using ten sera samples from
patients with stages III and IV pancreatic adenocarcinoma (PC),
chronic pancreatitis (CP), renal cell carcinoma (RC), esophageal
carcinoma (EC), and normal healthy controls (NL). Antibody-
captured proteins were probed with biotinylated ConA and
detected by streptavidinylated Alexa555. The bar graph and SEM
(error bars) shows the average signal and variation for each
group of samples. The group marked with a green star on top
can be significantly distinguished from the group marked with a
red star. (A) Serum amyloid p component (SAP-ConA);
(B) A1BG-ConA.
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conducted with a different set of samples. The results
(Fig. 3) are subjected to a t-test between each pair of
sample classes. A p-value of 0.035 was obtained for
A1BG between samples from chronic pancreatitis patients
and pancreatic cancer patients, whereas the p-value for
normal control and pancreatic cancer was 0.096 which is
above the significant level. For SAP, the difference
between normal control and pancreatic cancer patients is
significant (p-value, 0.026). The results demonstrate the
importance of the multiplexed biomarker measurement, as
neither of the two antibodies can significantly distinguish
cancer samples from normal and pancreatitis samples by
themselves, while together they create the capacity of
differentiating cancer samples from the other two groups
(Fig. 3).
Two more groups of samples (renal cell carcinoma and
esophageal cancer) were added to the experiment in which
the glycoproteins were probed with ConA which detects
mannosylation or complex biantennary glycans. The average
signals and the variation for each group of samples
are shown as a bar graph with error bars in Fig. 4. A decline
in ConA response on A1BG and SAP was found to distin-
guish pancreatic adenocarcinoma from normal and renal
Cell carcinoma, (po0.05 and o0.0001, respectively). A
decreased ConA response in SAP among patients with
pancreatic adenocarcinoma compared with chronic
pancreatitis was observed, but this did not reach statistical
significance, po0.11.
4 Concluding remarks
We have developed a method for high-throughput glyco-
protein biomarker screening using a novel bead-based
antibody-lectin glycoprotein assay. Compared with the
microarray platform, the new technique showed improved
sensitivity and reproducibility in glycan detection based on
the elimination of background noise due to lectin binding to
the antibodies for SNA and ConA. Some key steps, such as
array printing and slide scanning, that always introduce
spatial variation are eliminated when antibody-coupled
beads are used to perform the assay in a 96-well plate.
Additionally, the glycans on the bead-conjugated antibodies
were not reactive to lectin ConA and SNA, and hence the
glycan-blocking step can be avoided.
Using the bead-based assay, we discriminated glycosy-
lation patterns among normal and other disease states
with two glycoprotein biomarker candidates as a demon-
stration of the potential of this platform. These two glyco-
protein targets were chosen based on the most promising
results from the previous study. It should be noted that
although we could discriminate the disease and normal
groups based on the bead-based platform the results
will not necessarily be the same as the microarray
platform since the binding of the antibody to the surface and
subsequent glycoprotein capture and lectin affinity
will be different. Nevertheless, the different groups
could be discriminated with significance with the use of two
different lectins and could also be discriminated against
other disease states included. The lectin-based method
allows one to discriminate such disease states based on the
changes in glycan structure without the need for detailed
structural analysis of the sugar groups based on mass
analysis. This study is an initial demonstration of the
method but in future study will be multiplexed with addi-
tional antibodies on the beads and will use a larger set of
serum samples to verify the validity of the biomarkers. The
speed and utility of the bead-based method with detection by
flow cytometry will be essential, especially as the number of
samples increase.
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